Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

ClinicalTrials.gov ID: NCT00562965

Public ClinicalTrials.gov record NCT00562965. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (Cmc-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, Cd22- Positive, Follicular B-cell Non Hodgkin's Lymphoma

Study identification

NCT ID
NCT00562965
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
29 participants

Conditions and interventions

Interventions

  • cyclophosphamide Drug
  • dexamethasone Drug
  • fludarabine Drug
  • inotuzumab ozogamicin Drug
  • mitoxantrone Drug
  • prednisone/prednisolone Drug
  • rituximab Drug
  • vincristine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Mar 31, 2011
Completion
Mar 31, 2011
Last update posted
Jan 8, 2018

2007 – 2011

United States locations

U.S. sites
17
U.S. states
9
U.S. cities
16
Facility City State ZIP Site status
Facey Medical Group Mission Hills California 91345
Deaconess Clinic Evansville Indiana 47713
The Harry & Jeanette Weinberg Cancer Inst at Franklin Square Baltimore Maryland 21237
Newland Medical Associates Novi Michigan 48374
Newland Medical Associates, PC Southfield Michigan 48075
Park Nicollet Frauenshuh Cancer Center Saint Louis Park Minnesota 55426
Hematology and Oncology Associates Columbus Mississippi 39706
Hematology and Oncology Associates Corinth Mississippi 38834
Hematology and Oncology Associates at Bridgepoint Tupelo Mississippi 38801
Hackensack University Medical Center Hackensack New Jersey 07601
The Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601
Hematology Oncology Associates of Northern New Jersy Morristown New Jersey 07960
Advanced Oncology Associates Armonk New York 10504
Advanced Oncology Associates New Rochelle New York 10801
Marc Zimmerman, MD Pomona New York 10970
Avi Einzing, MD The Bronx New York 10461
Wenatchee Valley Medical Center Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00562965, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2018 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00562965 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →